A gastroretentive dosage form comprising a GABA analog, at least one swelling agent, at least one non-swelling pH dependent polymeric release retardant and at least one pharmaceutically acceptable excipient; wherein the GABA analog is selected from pregabalin, gabapentin, baclofen, vigabatrin, ((1 R,5S)-3-Amlnomethyl-1,5-dimethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; ((1 S,5R)-3-Aminomethyl-1,5-dimethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; ((1R,5S)-3-Aminomethyl-6,6-dimethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid; ((1S,5R)-3-Aminomethyl-6,6-dimethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid; ((1S,2S,5R)-2-Aminomethyl-6,6-dimethyl-bicyclo[3.1.0]hex-2-yl)-acetic acid; ((1 R,2S,5S)-2-Aminomethyl-6,6-dimethyl-bicyclo[3.1.0]hex-2-yl)-acetic acid; ((1S,2R,5R)-2-Aminomethyl-6,6-dimethyl-bicyclo[3.1.0]hex-2-yl)-acetic acid; ((1 R,2R,5S)-2-Aminomethyl-6,6-dimethyl-bicyclo[3.1.0]hex-2-yl)-acetic acid; ((1 R,5R,6S)-6-Aminomethyl-bicyclo[3.2.0]hept-6-yl)-acetic acid; ((1S,5S,6S)-6-Aminomethyl-bicyclo[3.2.0]hept-6-yl)-acetic acid; ((1 R,5R,6R)-6-Aminomethyl-bicyclo[3.2.0]hept- 6-yl)-acetic acid; ((1S,5S,6R)-6-Aminomethyl-bicyclo[3.2.0]hept-6-yl)-acetic acid; cis-((1S,2R,4S,5R)-3-Aminomethyl-2,4-dimethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; trans-((18,2R,48,5R)-3-Aminomethyl-2,4-dimethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; ((1S,5R,6S,7R)-3-Aminomethyl-6,7-dimethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; ((1S,5R,6R,7S)-3-Aminomethyl-6,7-dimethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; ((1R,2S,5S)-7-Aminomethyl-3,3-dimethyl-tricyclo[3.3.0.0]oct-7-yl)-acetic acid; ((1 R,6R,7S)-7-Aminomethyl-bicyclo[4.2.0]oct-7-yl)-acetic acid; ((1S,6S,7S)-7-Aminomethyl-bicyclo[4.2.0]oct-7-yl)-acetic acid; ((1 R,6R,7R)-7-Aminomethyl-bicyclo[4.2.0]oct-7-yl)-acetic acid; ((1S,6S,7R)-7-Aminomethyl-bicyclo[4.2.0]oct-7-yl)-acetic acid; ((1R,7R,8S)-8-Aminomethyl-bicyclo[5.2.0]non-8-yl)-acetic acid; ((1S,7S,8S)-8-Aminomethyl-bicyclo[5.2.0]non-8-yl)-acetic acid; ((1 R,7R,8R)-8-Aminomethyl-bicyclo[5.2.0]non-8-yl)-acetic acid; ((1S,7S,8R)-8-Aminomethyl-bicyclo[5.2.0]non-8-yl)-acetic acid. [(1 R,5R,6S)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid; [(1S,5S,6R)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid; (1RS,5RS,6RS)-6-(Aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid; and [(1RS,6RS,7SR)-7-(Aminomethyl)bicyclo[4.2.0]oct-7-yl]acetic acid or a combination thereof; wherein the amount of the swelling agent in the dosage form is from 5% to 70% by weight of the dosage form, and wherein the swelling agent(s) swell voluminously in the presence of gastric contents to increase the dosage form size such that its passage through the pyrolus is precluded; and wherein the non-swelling pH dependent polymeric release retardant is present in the formulation in an amount from 2% to 85% by weight of the dosage form and wherein the non-swelling pH dependent polymeric release retardant is polymethacrylic acid polymer, or a derivative thereof selected from methyl acrylate' acrylic acid copolymer, methyl acrylate'methacrylic acid copolymer, methacrylic acid'methyl methacrylate copolymer, methacrylic acid'ethyl acrylate copolymer, methyl acrylate methacrylic acid octyl acrylate copolymer or a combination thereof.